search
Back to results

Volemic Resuscitation in Sepsis and Septic Shock

Primary Purpose

Hemodynamic Instability, Sepsis, Septic Shock

Status
Unknown status
Phase
Not Applicable
Locations
Romania
Study Type
Interventional
Intervention
Flotrac/Ev1000
Standard ICU monitorisation
VolumeView/Ev1000
Sponsored by
Iuliu Hatieganu University of Medicine and Pharmacy
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemodynamic Instability focused on measuring sepsis, hemodynamic monitoring, septic shock, volemic resuscitation, fluid resuscitation

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: sepsis and septic shock (acording to the Sepsis Campaign 2016 crieria) patients with medical or surgical pathology which are admitted in the ICU unit in the first 12 hours after the onset of the sepsis/septic shock

Exclusion Criteria:

age less then 18 and more then 85 cardiac valvular pathology with hemodynamic importance cardiac failure NYHA IV primary or secondary pulmonary hypertension with hemodymanic impact with onset before the onset of the septic pathology Severe liver failure (Child-Pugh C) Anuric renal failure Pregnant women Patient who refuse blood products adminitration End-stage cancer

Sites / Locations

  • Cluj County Emenrgency HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Sepsis grup 1

Sepsis grup 2

Soc septic grup 1

Soc septic grup 2

Arm Description

Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours

Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours

Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours

Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours

Outcomes

Primary Outcome Measures

Tissue perfusion at six hours (composite)
Tissue perfusion at six hours: urinary output, blood pressure, lactate clearance, skin aspect

Secondary Outcome Measures

Duration of cardiovascular failure
need of vasopressor support: at the end of the 6 hours resuscitation period and one, two, six and twelve days
Duration of respiratory failure
respiratory failure at oane day, two days, six days and twelve days
Duration of acute renal failure
Duration of acute renal failure (need of dialysis) at 5 days, at 10 days, at 30 days and at 60 days
Duration of ICU stay and in hospital stay
Duration of ICU stay and in hospital stay
Discharge status at 60 days
Discharge status at 60 days:Not discharged ,Discharge to another acute care hospital,Discharged to nursing home,Discharged home ,Other or unknown
all cause mortality at 60 days
all cause mortality at 60 days

Full Information

First Posted
September 1, 2015
Last Updated
December 13, 2016
Sponsor
Iuliu Hatieganu University of Medicine and Pharmacy
search

1. Study Identification

Unique Protocol Identification Number
NCT02565251
Brief Title
Volemic Resuscitation in Sepsis and Septic Shock
Official Title
Volemic Resuscitation in Sepsis and Septic Shock
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Unknown status
Study Start Date
September 2015 (undefined)
Primary Completion Date
September 2017 (Anticipated)
Study Completion Date
September 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Iuliu Hatieganu University of Medicine and Pharmacy

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Severe sepsis and septic shock are among the leading causes of morbidity and mortality in patients admitted in the ICU, being responsible for approximately 200000 deaths/year in the USA and 150000 in Europe. Recognizing the early signs of sepsis and the different stages of this condition may lower the associated morbidity and mortality. The hemodynamic profile of the septic shock is characterized by the presence of the distributive shock, on which we can add elements from the hypovolemic and cardiogenic shocks. The objecive of this study is to optimize the volemic resuscitation of the severe septic and of the septic shock patient using two minimally invasive methods of hemdynamic monitoring which both use the same device (Edwards Lifescience). In the same time hemodinamic data will be colected by mesuring the inferior vena cava diameter.
Detailed Description
Severe sepsis and septic shock are among the leading causes of morbidity and mortality in patients admitted in the ICU, being responsible for approximately 200000 deaths/year in the USA and 150000 in Europe . Recognizing the early signs of sepsis and the different stages of this condition may lower the associated morbidity and mortality. The hemodynamic profile of the septic shock is characterized by the presence of the distributive shock, on which we can add elements from the hypovolemic and cardiogenic shocks. The persistence of hypotension after adequate fluid load is the result of low vascular resistance and myocardial dysfunction and calls for certain specific correctional measures. The diffrent hemodynamic profiles which can be found in the different stages of the septic shock and their dificult clinical identification led to the development of varoius hemodynamic monitoring techniques and devices. These techniques can be classified into invasive and minimally invasive, calibrated and uncalibrated. The major diffrences among these tecniques is the easyness of utilisation and the acuracy of the data obtained. Inclusion Criteria: severe sepsis and septic shock (acording to the Sepsis Campaign 2013 crieria) patients with medical or surgical pathology which are admitted in the ICU unit in the first six hours after the onset of the severe sepsis/septic shock. The exclusion criteria of the patients are age less then 18 and more then 75, cardiac valvular pathology with hemodynamic importance, cardiac failure NYHA III și IV, primary or secondary pulmonary hypertension with hemodymanic impact with onset before the onset of the septic pathology,severe liver failure (Child-Pugh C), anuric renal failure, pregnant women, patient who refuse blood products adminitration, end-stage cancer. The objecive of this study is to optimize the volemic resuscitation of the severe septic and of the septic shock patient using two minimally invasive methods of hemdynamic monitoring which both use the same device (Edwards Lifescience). In the same time hemodinamic data will be colected by mesuring the inferior vena cava diameter. The primary outcome is the adecuacy of tissue perfusion at six hours (urinary output, blood pressure, lactate clearance, skin aspect). The secondary oucomes are duration of cardiovascular failure at the end of the 6 hours resuscitation period/ number of days, duration of respiratory failure (need of mechanical ventilation, number of days), duration of acute renal failure (need of dialysis) at ICU discharge/10/30/60 days, duration of ICU stay and in hospital stay, discharge status at 60 days (not discharged ,discharge to another acute care hospital, discharged to nursing home, discharged home ,other or unknown and all cause mortality at 60 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemodynamic Instability, Sepsis, Septic Shock
Keywords
sepsis, hemodynamic monitoring, septic shock, volemic resuscitation, fluid resuscitation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sepsis grup 1
Arm Type
Experimental
Arm Description
Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
Arm Title
Sepsis grup 2
Arm Type
Experimental
Arm Description
Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
Arm Title
Soc septic grup 1
Arm Type
Experimental
Arm Description
Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
Arm Title
Soc septic grup 2
Arm Type
Experimental
Arm Description
Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours
Intervention Type
Device
Intervention Name(s)
Flotrac/Ev1000
Intervention Description
Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
Intervention Type
Device
Intervention Name(s)
Standard ICU monitorisation
Intervention Description
Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
Intervention Type
Device
Intervention Name(s)
VolumeView/Ev1000
Intervention Description
Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
Primary Outcome Measure Information:
Title
Tissue perfusion at six hours (composite)
Description
Tissue perfusion at six hours: urinary output, blood pressure, lactate clearance, skin aspect
Time Frame
six hours
Secondary Outcome Measure Information:
Title
Duration of cardiovascular failure
Description
need of vasopressor support: at the end of the 6 hours resuscitation period and one, two, six and twelve days
Time Frame
at the end of the 6 hours resuscitation period and one, two, six and twelve days
Title
Duration of respiratory failure
Description
respiratory failure at oane day, two days, six days and twelve days
Time Frame
respiratory failure at oane day, two days, six days and twelve days
Title
Duration of acute renal failure
Description
Duration of acute renal failure (need of dialysis) at 5 days, at 10 days, at 30 days and at 60 days
Time Frame
at 5 days, at 10 days, at 30 days and at 60 days
Title
Duration of ICU stay and in hospital stay
Description
Duration of ICU stay and in hospital stay
Time Frame
status at 5 days, at 10 days, at 30 days and at 60 days
Title
Discharge status at 60 days
Description
Discharge status at 60 days:Not discharged ,Discharge to another acute care hospital,Discharged to nursing home,Discharged home ,Other or unknown
Time Frame
at 60 days
Title
all cause mortality at 60 days
Description
all cause mortality at 60 days
Time Frame
60 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: sepsis and septic shock (acording to the Sepsis Campaign 2016 crieria) patients with medical or surgical pathology which are admitted in the ICU unit in the first 12 hours after the onset of the sepsis/septic shock Exclusion Criteria: age less then 18 and more then 85 cardiac valvular pathology with hemodynamic importance cardiac failure NYHA IV primary or secondary pulmonary hypertension with hemodymanic impact with onset before the onset of the septic pathology Severe liver failure (Child-Pugh C) Anuric renal failure Pregnant women Patient who refuse blood products adminitration End-stage cancer
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Natalia Hagau, Professor
Phone
0742272385
Email
hagaunatalia@gmail.com
Facility Information:
Facility Name
Cluj County Emenrgency Hospital
City
Cluj-Napoca
State/Province
Cluj
ZIP/Postal Code
400006
Country
Romania
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Natalia Hagau, Professor
Phone
0742272385
Email
hagaunatalia@gmail.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
24635774
Citation
Lilly CM. The ProCESS trial--a new era of sepsis management. N Engl J Med. 2014 May 1;370(18):1750-1. doi: 10.1056/NEJMe1402564. Epub 2014 Mar 18. No abstract available.
Results Reference
result
PubMed Identifier
25272316
Citation
ARISE Investigators; ANZICS Clinical Trials Group; Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, Webb SA, Williams P. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014 Oct 16;371(16):1496-506. doi: 10.1056/NEJMoa1404380. Epub 2014 Oct 1.
Results Reference
result
PubMed Identifier
25776532
Citation
Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, Jahan R, Harvey SE, Bell D, Bion JF, Coats TJ, Singer M, Young JD, Rowan KM; ProMISe Trial Investigators. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015 Apr 2;372(14):1301-11. doi: 10.1056/NEJMoa1500896. Epub 2015 Mar 17.
Results Reference
result
PubMed Identifier
24635771
Citation
Russell JA. Is there a good MAP for septic shock? N Engl J Med. 2014 Apr 24;370(17):1649-51. doi: 10.1056/NEJMe1402066. Epub 2014 Mar 18. No abstract available.
Results Reference
result
PubMed Identifier
24635770
Citation
Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, Mira JP, Dequin PF, Gergaud S, Weiss N, Legay F, Le Tulzo Y, Conrad M, Robert R, Gonzalez F, Guitton C, Tamion F, Tonnelier JM, Guezennec P, Van Der Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard JD, Herve F, du Cheyron D, Guerin C, Mercat A, Teboul JL, Radermacher P; SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014 Apr 24;370(17):1583-93. doi: 10.1056/NEJMoa1312173. Epub 2014 Mar 18.
Results Reference
result
PubMed Identifier
23663301
Citation
Bakker J, Nijsten MW, Jansen TC. Clinical use of lactate monitoring in critically ill patients. Ann Intensive Care. 2013 May 10;3(1):12. doi: 10.1186/2110-5820-3-12.
Results Reference
result
PubMed Identifier
24280808
Citation
Cecconi M, Arulkumaran N, Kilic J, Ebm C, Rhodes A. Update on hemodynamic monitoring and management in septic patients. Minerva Anestesiol. 2014 Jun;80(6):701-11. Epub 2013 Nov 26.
Results Reference
result
PubMed Identifier
20096600
Citation
Cecconi M, Hofer C, Della Rocca G, Grounds RM, Rhodes A. Assessing agreement in cardiac output monitoring validation studies. J Cardiothorac Vasc Anesth. 2010 Aug;24(4):741; author reply 741-2. doi: 10.1053/j.jvca.2009.11.008. Epub 2010 Jan 22. No abstract available.
Results Reference
result
PubMed Identifier
20537159
Citation
Monnet X, Anguel N, Naudin B, Jabot J, Richard C, Teboul JL. Arterial pressure-based cardiac output in septic patients: different accuracy of pulse contour and uncalibrated pressure waveform devices. Crit Care. 2010;14(3):R109. doi: 10.1186/cc9058. Epub 2010 Jun 10.
Results Reference
result
PubMed Identifier
23361128
Citation
Marque S, Gros A, Chimot L, Gacouin A, Lavoue S, Camus C, Le Tulzo Y. Cardiac output monitoring in septic shock: evaluation of the third-generation Flotrac-Vigileo. J Clin Monit Comput. 2013 Jun;27(3):273-9. doi: 10.1007/s10877-013-9431-z. Epub 2013 Jan 30.
Results Reference
result
PubMed Identifier
17285286
Citation
Antonelli M, Levy M, Andrews PJ, Chastre J, Hudson LD, Manthous C, Meduri GU, Moreno RP, Putensen C, Stewart T, Torres A. Hemodynamic monitoring in shock and implications for management. International Consensus Conference, Paris, France, 27-28 April 2006. Intensive Care Med. 2007 Apr;33(4):575-90. doi: 10.1007/s00134-007-0531-4.
Results Reference
result

Learn more about this trial

Volemic Resuscitation in Sepsis and Septic Shock

We'll reach out to this number within 24 hrs